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Abstract. Background: Na+/H+ exchanger regulatory factor
1 (NHERF1) has been reported to interact with many cancer-
related proteins. We recently identified a novel NHERF1
mutation (E43G) in breast tumours. Materials and Methods:
The candidates of NHERF1 mutation were identified in breast
cancer tissues by polymerase chain reaction and DNA
sequencing. Wild-type NHERF1 and E43G mutation were
expressed in NHERF1-knockdown cells (MCF7ΔNHERF1)
and low-NHERF1-expressing cells (SKMES-1). The effects of
mutated NHERF1 on cell functions were examined using in
vitro methods. Glutathione S-transferase pull-down assays and
western blotting were performed to study the effects of
NHERF1 mutation on its interaction with cancer-related
proteins. Results: Compared to wild-type NHERF1, expression
of the mutated NHERF1 failed to suppress malignant traits in
cancer cells, attenuated interaction of NHERF1 protein with
epidermal growth factor receptor (EGFR), and inactivated its
inhibition of EGF-induced Akt and extracellular regulated
protein kinases (ERK) activation. Conclusion: The results
show the causal role of NHERF1 in the regulation of the
EGFR pathway and the progression of breast cancer.
During the past decade, the systemic therapeutic
management of breast cancer has undergone a significant
transformation. Without targeted therapies, conventional
treatment with cytotoxic agents has maximized its potential
in terms of patient survival for most types of cancers.
Enhanced understanding of the pathogenesis of tumour cell
growth and metastasis has led to the identification of growth
signalling pathways as targets for these directed therapies
(1). Epidermal growth factor receptor (EGFR) is over-
expressed or activated in breast cancer (2, 3), and a number
of drugs specifically targeting this tyrosine kinase have been
developed over the years as anticancer agents (4, 5).
Evidence in cells has shown that the scaffolding protein
Na+/H+ exchanger regulatory factor 1 (NHERF1) can
associate with EGFR to regulate its trafficking and
expression in breast cancer cells and, modulating its role in
progression and metastasis of breast cancer (6).
NHERF1 is a protein with two structural domains named
PDZ1 and PDZ2 followed by an ezrin–radixin–moesin-binding
region (7, 8). These domains bind to the carboxy-terminal parts
of transporters or receptors (9-11). Hence, NHERF1 binds to
the C-terminal of EGFR and stimulation with EGF induces
interaction of NHERF1 with EGFR to regulate localization,
degradation and function of the latter (12). NHERF1 can
suppress EGF-induced proliferation of breast cancer cells by
inhibiting EGFR phosphorylation and blocking EGFR
downstream signalling in breast cancer cells (13).
Loss of heterozygosity (LOH) at the NHERF1 gene locus
(17q25.1) is found in more than 50% of human breast tumours
(14), whereas being less frequent in other tumour types,
suggesting a pivotal role of NHERF1 during breast
carcinogenesis (14). Previous reports have suggested that
NHERF1 plays a tumour-suppressor role in breast cancer cell
lines. NHERF1 inhibited canonical Wnt signalling and Wnt-
dependent cell proliferation in MCF7 and MDA MB-231 cells
(15). By interaction with phosphatase and tensin homolog
deleted on chromosome 10 (PTEN), NHERF1 counter-
balanced phosphatidylinositol 3-kinase/Akt (PI3K/Akt)
oncogenic signaling and enhanced cell responses to platelet-
derived growth factor receptor (PDGFR) inhibitor in breast
cancer cell lines (16). NHERF1 knockdown accelerated cell-
cycle progression, accompanied by increased expression of
cyclin E and elevated retinoblastoma phosphorylation level
(14). Furthermore, the mammary glands of NHERF-1-
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knockout mice exhibit increased mammary duct density
accompanied by increased proliferation and β-catenin activity
(17). Our previous studies also showed that over-expression of
NHERF1 reduced cell proliferation, motility, and invasion of
low-NHERF1-expressing SKMES-1 cells, and knockdown of
NHERF1 enhanced the migratory and invasive ability of MCF-
7 cells (18). The results of both gain-of-function and loss-of-
function studies indicated that NHERF1 acts as a tumour
suppressor in tumour cells.
In the present study, a novel NHERF1 gene mutation
(E43G) was identified in a patient with breast cancer. The
effects of wild-type (WT) and NHERF1 mutation E43G on
the proliferation, migration, and adhesion of tumour cells
were investigated in order to gain insight into NHERF1
function, and to improve our understanding of the role of
NHERF1 in tumour development and progression.
Materials and Methods
Cell lines and culture. A human breast cancer cell line, MCF-
7∆NHERF1, with low expression of NHERF1, was constructed
previously (18), by stably expressing a ribozyme targeted to
NHERF1. Non-small cell lung cancer cell line SKMES-1 was
obtained from the European Collection for Animal Cell Culture
(Porton Down, Salisbury, UK). Cos-7 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA). All cells
were maintained in Dulbecco’s modified Eagle's medium (DMEM)
supplemented with 10% foetal calf serum, 1% penicillin and
streptomycin (Gibco BRC, Paisley, UK) in an incubator at 37˚C,
with 5% CO2, and 95% humidity. 
Human breast specimens. A total of 20 breast samples were
obtained from patients with breast cancer. These tissues were
collected immediately after mastectomy, and snap-frozen in liquid
nitrogen, with the approvals of the Local Ethical Committee
(2013SY15). None of the patients had any underlying medical
condition and none were taking any medication. 
Mutational analyses of NHERF. The genomic DNA from 20 frozen
breast cancer tissues was extracted using the DNeasy kit (Qiagen,
Hilden, Germany). All six exons of NHERF1 gene were amplified
by PCR using primers corresponding to the neighbouring intronic
sequences, and further analyzed by single-strand conformation
polymorphism (SSCP) as previously described (19). The sequences
of the intronic primers used for the polymerase chain reaction have
already been published (20). The candidates of the mutant gene
were then identified by DNA sequencing.
Preparation of expression vectors. Wild-type glutathione S-
transferase (GST)–NHERF1 construct was kindly provided by Dr.
Jiale Dai (MD Anderson Cancer Center, Houston, TX, USA).
GST–NHERF1 mutation construct was generated from the wild type
with the use of Fast MultiSite Mutagenesis System kit (TransGen,
Beijing, China). cDNA of NHERF1-WT and mutation were cloned
into pEASY™-M2 vector using pEASY-Blunt M2 Expression Kit
(TransGen) according to the manufacturer’s instructions. All
constructs were verified by sequencing.
Cell transfection. Subconfluent cells were transfected with NHERF1
expression constructs using lipofectamine reagent according to the
manufacturer’s instructions (Invitrogen, Waltham, MA, USA). MCF-
7∆NHERF1 and SKMES-1 cells were selected in culture medium
containing 600 μg/ml G418 for 21 days to generate stable NHERF1-
expressing cell lines. NHERF1 expression was verified by western
blotting.
Wound-healing assay. The migratory properties of cells were
assessed using a wound-healing assay. A variety of cells were
seeded at a density of 2×105 cells/well into a 24-well plate and
allowed to reach confluence. The layer of cells was then scraped
with a fine-gauge needle to create a wound of approximately 1500
μm. Images of the wound were recorded under a phase-contrast
microscope at different time points (0 h, 6 h, 12 h, 24 h). Wound
closure/cell migration was evaluated with Image-Pro plus (National
Institutes of Health, Maryland, USA).
GST pull-down assays and western blotting. GST pull-down assays
and western blotting was performed as described previously (15). Anti-
NHERF1was purchased from Becton Dickinson Company (Franklin
Lake, New Jersey, USA), anti-extracellular regulated protein
kinases(ERK) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), anti-phospho-Akt (Ser473), anti-Akt, anti-EGFR, anti-phospho-
EGFR (Tyr1173) were obtained from Cell Signaling Technology
(Danvers, MA, USA). Anti-phospho-mitogen-activated protein kinase
(MAPK)1/2 (ERK 1/2) was from Millipore (Massachusetts, USA).
Statistical analysis. The results were assessed using non-paired
(two-sided) Student’s t-test. A p-value of less than 0.05 was
considered statistically significant. Each assay was repeated at least
three times. 
Results
Identification of the NHERF1E43G mutation in breast
cancer. The coding region and the intron-exon junctions of
the NHERF1 gene were analyzed by PCR-SSCP (Figure 1A)
and confirmed by DNA sequencing (Figure 1B). A
previously unreported sequence variant (GAG to GGG), that
would result in a switch of codon 43 (Glu-Gly), was
identified in the first exon of NHERF1 in a patient with
medullary breast carcinoma. The mutation corresponded to
a conserved basic residue in the PDZ1 domain (Figure 1C).
The alignment of the NHERF1 protein sequence showed that
glutamic acid 43 was highly conserved in the NHERF1
PDZ1 domain throughout evolution and in the PDZ1 domain
of the other species in NHERF protein family (Tables I and
II), suggesting that it plays an important role in the function
of this domain. Furthermore this variant was not found in the
1000 genomes database (http://browser.1000genomes.org).
NHERF1E43G mutation impaired tumour-suppressive effects
on malignant cell phenotypes. Previous studies on the tumour-
suppressor functions of NHERF1 were carried out by
knockdown or over-expression of NHERF1 in cancer cell lines
(14, 17, 21). Our previous studies also showed that NHERF1
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behaves as a tumour suppressor in breast cancer cells (18). To
examine the effects of the E43G mutation on the tumour-
suppressive function of NHERF1, it was transfected into the
low-NHERF1-expressing cancer cells SKMES-1 and MCF-
7ΔNHERF1. Its expression was assessed by western blotting.
The expression level of NHERF1 was considerably increased
in the stably-transfected cells compared to parental and vector
control cells, and in cells with E43G mutation was expressed
at similar levels to NHERF1-WT (Figure 2A and B). Major
malignant phenotypes, including cell proliferation and
migration, were then evaluated. Compared to vector control
cells, cell proliferation was suppressed by up to 22% and 46%,
respectively, in SKMES-1 (on day 4) and MCF-7ΔNHERF1 (on
day 4) cells overexpressing NHERF1-WT (Figure 2C and D),
cell migration was also reduced by up to 50% and 30%
respectively at 24 h (Figure 2E, F). NHERF1E43G mutation
was able to rescue the cell proliferation and migration that was
suppressed by NHERF1-WT, since there were no significant
differences in proliferation and migration rates between
control and the mutant-expressing cells (Figure 2C-F). These
results indicate that NHERF1-WT acted as a tumour
suppressor in SKMES-1 and MCF-7ΔNHERF1 cells, and the
breast cancer-derived NHERF1 mutation E43G abolished its
suppressor effects on cell proliferation and migration.
NHERF1E43G mutation altered interaction of NHERF1
protein with EGFR. It has been shown that NHERF1
interacts with EGFR through its PDZ1 domain and inhibits
EGFR signalling in breast cancer cells (12, 13, 22). To
further investigate if NHERF1 mutation could affect the
interaction between NHERF1 and EGFR, various
GST–NHERF1 fusion protein beads were incubated with
protein extracts from COS-7 cells, and EGFR was then
detected in the pull-down complex. GST–NHERF1-WT
associated robustly with endogenous EGFR protein, whereas
GST alone did not. Although NHERF1-E43G was able to
bind to EGFR, its affinity to EGFR was reduced by almost
40% compared to that of NHERF1-WT (Figure 3). These
data indicate that NHERF1E43G mutation weakened the
interaction of NHERF1 with EGFR.
NHERF1E43G mutation inactivated NHERF1 inhibition of
EGF-induced Akt and ERK activation. NHERF1 has been
reported to suppress the phosphorylation activation of EGFR,
blocking EGFR downstream signaling in breast cancer cells
(13), which in turn controls important biological functions
such as cell proliferation and migration (23). Since NHERF1
mutation affected NHERF1–EGFR complex formation, it
was reasonable to assume that the mutation could also affect
EGFR signaling. To test this hypothesis, we detected
phosphorylation of EGFR, Akt and ERK in MCF7ΔNHERF1
cells transfected with different NHERF1 constructs. EGFR
(Figure 4A), Akt (Figure 4B) and ERK (Figure 4C) were all
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Figure 1. A novel Na+/H+ exchanger regulatory factor 1 (NHERF1)
mutation was identified in patients with medullar breast carcinoma.
NHERF1 mutation in exon 1 was analysed by single-strand
conformation polymor-phism(SSCP) analysis. A: Abnormal migratory
SSCP band patterns for the mutation (T) are demonstrated as compared
with normal (N). B: A previously unreported sequence variant (GAG to
GGG) was identified by sequencing, which would result in a switch of
codon 43 (Glu-Gly). C: The mutation corresponded to a conserved basic
residue in the PDZ I domain.
dramatically phosphorylated in both MCF7ΔNHERF1 parental
and vector control cells following 5 min stimulation with 100
ng/ml EGF. NHERF1-WT over-expression significantly
inhibited Akt and ERK activation and blocked EGF-induced
EGFR phosphorylation. However, the NHERF1 mutation
E43G abolished NHERF1-WT inhibition of EGFR, Akt and
ERK activation (Figure 4), Meanwhile the base levels of Akt
and ERK activation were not detectably different in cells
transfected with different NHERF1 constructs (data not
shown). Taken together, these data suggest that cancer-
derived NHERF1 mutation (E43G) abolished the inhibition
of the phosphorylational activation of EGFR and its
downstream signaling through Akt and ERK signaling
pathways induced by EGF.
NHERF1E43G mutation resulted in loss of EGF-induced
tumour-suppressor effects of NHERF1-WT. Since the
mutation of NHERF1 affects EGFR activation in breast
cancer cells, NHERF1 mutation could potentially mediate
changes in cell migration of these breast cancer cells. EGF-
induced cell migration was investigated in cells stably
transfected with NHERF1-WT and mutation in order to
explore which potential signaling transduction proteins were
modulated by NHERF1. After pre-culture in serum-free
medium for 36 h, cells were treated with 100 ng/ml EGF.
NHERF1-WT significantly inhibited the proliferation and
migration rate of MCF-7ΔNHERF1 cells induced by EGF
compared to parental and vector control cells. In contrast,
NHERF1 E43G mutation removed the inhibitory effect of
NHERF1 in the EGF-induced malignant cell phenotypes
(Figure 5). Taken together, these results suggest that NHERF1
inhibited EGF-induced cell malignant phenotypes in breast
cancer cells, but the E43G mutation resulted in complete loss
of the tumour-suppressor effects of NHERF1-WT.
Discussion
Breast cancer is regarded as a heterogeneous group of
tumours with different outcomes and responses to
treatment. Recent reports suggest a fundamental role for
NHERF1 in human breast cancer. Down-regulation of
endogenous NHERF1 in breast cancer cells promoted
proliferation, tumourigenic ability, and delayed the turnover
of PDGF-induced Akt phosphorylation (24). In our
previous study, over-expression of NHERF1 in a breast
cancer cell line suppressed cell proliferation by promoting
apoptosis and inhibiting ERK activation (18), suggestive of
a tumour-suppressive role for NHERF1. However,
contrasting results have recently been reported. NHERF1
over-expression in breast tumours is associated with tumour
stage, metastatic progression, and poor prognosis (25),
implying that NHERF1 is a potential oncoprotein. These
contradictory reports suggest a complicated role for
NHERF1 in breast cancer. 
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Table I. Glutamic acid 43 was highly conserved in the NHERF1 PDZ1 domain throughout different species.
UniProt Accession Number Amino acid sequence Species
O14745 FHLHGEKGKLGQYIRLVEPGSPAEKAGLLAGDRLV HUMAN
P70441 FHLHGEKGKVGQFIRLVEPGSPAEKSGLLAGDRLV MOUSE
Q9JJ19 FHLHGEKGKVGQFIRLVEPGSPAEKSGLLAGDRLV RAT
Q4R6G4 FHLHGEKGKLGQYIRLVEPGSPAEKAGLLAGDRLV MACAQUE
Q3SZK8 FHLHGEKGKVGQYIRLVEPGSPAEKSGLLAGDRLV BOVINE
Q28619 FHLHGEKGKVGQYIRLVEPGSPAEKAGLLAGDRLV RABBIT
Q5ZM14 FHLHGEKGKPGQYIRLVEAGSPAERSGLRAGDRLL CHICKEN
*All protein sequences were obtained from UniProt.
Table II. Glutamic acid 43 was highly conserved in the PDZ1 domain of NHERF1 and NHERF2 proteins.
UniProt Accession Number Amino acid sequence Protein & Species
O14745 FHLHGEKGKLGQYIRLVEPGSPAEKAGLLAGDRLV NHERF1 HUMAN
Q15599 FHLHGEKGRRGQFIRRVEPGSPAEAAALRAGDRLV NHERF2 HUMAN
Q9JHL1 FHLHGEKGRRGQFIRRVEPGSPAEAAALRAGDRLV NHERF2 MOUSE
Q920G2 FHLHGEKGRRGQFIRRVEPGSPAEAAALRAGDRLV NHERF2 RAT
Q8SQG9 FHLHGEKGRRGQFIRRVEPGSPAEAAALRAGDRLV NHERF2 RABBIT
* All protein sequences were obtained from UniProt.
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Figure 2. Breast cancer-derived Na+/H+ exchanger regulatory factor 1(NHERF1) E43G mutation abolished the antitumor effects of NHERF1 on cell
migration in SKMES1 and MCF-7ΔNHERF1 cells. The wild-type NHERF1 (WT) and the E43G mutation were stably transfected into SKMES1 and
MCF-7ΔNHERF1 cells and detected with anti-NHERF (A, B). E43G mutation impaired tumor-suppressive function of NHERF1, including cell
proliferation (C, D) and migration (E, F). The results represent mean values±SD of three independent experiments. *p<0.05, **p<0.01. GAPDH:
Glyceraldehyde-3-phosphate dehydrogenase.
In this study, the coding region and the intron-exon
junctions of the NHERF1 gene derived from 20 breast cancer
tissues were analyzed. A novel NHERF1 sequence variant
(GAG to GGG) resulting in a switch of codon 43 (Glu-Gly)
was firstly identified (Figure 1B). The mutation corresponded
to a conserved basic residue in the PDZ1 domain (Figure 1C).
The sequence is highly conserved according to the alignment
of the sequence of PDZ1 of NHERF1 protein in various
animals (Tables I and II). These data suggest that a variation in
PDZ1 domain could greatly impact the cell phenotype or even
cause cell death, making it hard for cells to survive and to
identify cells carrying the sequence variation in the PDZ
domain. Results of the cell function assays showed that the
E43G mutation significantly inactivated the NHERF1
suppression of proliferation and migration οf MCF7ΔNHERF1
and SKMES-1 cells. These findings further support the
tumour-suppressive function of NHERF1 in tumour cells, and
suggest that the NHERF1 mutation may play a causal role in
tumour development and progression. Here, we demonstrated
that NHERF1 interacted with EGFR (Figure 3) and suppressed
EGF-induced proliferation and migration of MCF-7ΔNHERF1
cells (Figure 5) by inhibiting EGFR phosphorylation (Figure
4A) and blocking EGFR downstream signaling in breast
cancer cells (Figure 4B and C). While NHERF1 E43G
mutation attenuated the interaction of NHERF1 protein with
EGFR (Figure 3) and markedly inactivated NHERF1-
suppressed activation of Akt and ERK upon EGF stimulation.
Hence, loss of suppression of ERK and Akt activities in the
cells carrying NHERF1 mutations might explain their
increased malignant cell phenotypes.
The EGFR is one of four members of the HER family of
receptor tyrosine kinases. Triggering of EGFR with its
potential ligands (EGF, ransforming growth factor-α or
amphiregulin) lead to homo- and heterodimerization of the
ErbB receptors, and subsequent autophosphorylation of the
tyrosine domain leads to downstream signalling of Ras/MAPK
(26), PI(3)K/Akt (27), phospholipase C- protein kinase C (28),
and janus kinase/signal transducers and activators of
transcription (29) pathways. This in turn resultsin cell
differentiation and migration. NHERF1, as a signaling adaptor,
can associate with EGFR to regulate the latter's functional
expression and activation in breast cancer cells and,
modulating its role in progression and response to treatment.
The C-terminus of EGFR interacts with NHERF1 through
its PDZ1 domain (30), where the E43G mutation of NHERF1
was identified and located in. It could be imagined that the
change in the hydrophobic property of the amino acid
residues, [e.g. the acidic amino acid residue (Glu) substituted
by the non-polar aliphatic amino acid residue (Gly)], could
lead to a change of the spatial structure of the protein,
resulting in the different biological activities of NHERF1 in
cells. In fact, NHERF1 E43G mutation altered the binding
affinity of NHERF1 to EGFR (Figure 3), and led to the loss of
its suppression in the EGFR pathway (Figure 4). However, the
mutation could be a useful tool for studying the effects of
NHERF1 on the regulation of the EGFR pathway in cells and
the progression and metastasis of breast cancer through the
EGFR pathway. Moreover, the one-point mutation in the
scaffold protein NHERF1 caused the observed changes in the
abilities of proliferation and migration of cells, suggesting that
when studying the regulation of the EGFR pathway in breast
cancer, some scaffold proteins involved in the pathway should
be considered.
In conclusion, a novel NHERF1 gene mutation (E43G)
was isolated and identified in breast tumours. Compared to
wild-type NHERF1, expression of the mutated NHERF1
failed to suppress malignant properties of human cancer
cells. The E43G mutation attenuated the interaction between
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Figure 3. Na+/H+ exchanger regulatory factor 1 (NHERF1) E43G
mutation altered its interaction with epidermal growth factor receptor
(EGFR). Glutathione S-transferases (GST)–NHERF1 beads were
incubated with COS-7 cell lysates, and then the pull-down complexes
were subjected to EGFR immunoblotting. A: NHERF1 mutation (E43G)
weakened NHERF1 interaction with EGFR by GST pull-down assay.
The Coomassie blue-stained gel was used to visualize the same amount
of input of fusion proteins. B: The signals were quantified by
densitometric analysis. The results represent mean values±SD of three
independent experiments. **p<0.01. WT: Wild-type.
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Figure 4. Na+/H+ exchanger regulatory factor 1(NHERF1) E43G mutation caused loss-of-function of NHERF1 inhibition of Akt and extracellular
regulated protein kinases(ERK) activation induced by epidermal growth factor(EGF). MCF-7ΔNHERF1 cells stably transfected with various NHERF1
constructs were serum starved for 36 h and then stimulated with or without EGF for 5 min. Immunoblot was detected with anti-pY1173EGFR (A), anti-
EGFR (A), anti-pS473Akt (B), anti-Akt (B), anti-p-ERK (C) and anti-ERK (C). The signals were quantified by densitometric analysis. Data are given
as the fold that of stimulated parental cells. The results represent mean values±SD of three independent experiments. *p<0.05, **p<0.01. WT: Wild-type.
NHERF1 and EGFR proteins, which inactivated NHERF1
inhibition of EGF-induced Akt and ERK activation, resulting
in the total loss of suppression of NHERF1 in EGF-induced
malignant cell phenotypes. These results further demonstrate
the functional consequences of breast cancer-derived
NHERF1 mutation (E43G), and suggest the causal role of
NHERF1 in the regulation of the EGFR signaling pathway
and the progression of breast tumours. 
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